Nectar Lifesciences Limited

35.26

INR
+0.69(+2.00%)
As of November 14, 2024 10:00:00 AM

About Nectar Lifesciences Limited

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
0.49x
Operating MarginLast 12 months
6.78
+63.1% quarterly YoY
Market Cap
808.83 CrINR
Employees
1686
CEO
NA
Website

Nectar Lifesciences Limited

35.26

INR
+0.69(+2.00%)
As of November 14, 2024 10:00:00 AM

About Nectar Lifesciences Limited

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
0.49x
Operating MarginLast 12 months
6.78
+63.1% quarterly YoY
Market Cap
808.83 CrINR
Employees
1686
CEO
NA
Website